Author:
Schenke Simone,Zimny Michael,Kreißl Michael C.
Abstract
AbstractFor the assessment of hyperparathyroidism besides cervical ultrasound, 99 mTc-Sestamibi (MIBI) imaging is being used on a routine basis in nuclear medicine practice. MIBI is a positively charged complex, which is bound in mitochondria rich parathyroidal tissue and shows a reduced washout as compared to normal thyroid tissue. This characteristic is used during dual-phase imaging by acquiring early and late images.In order to better localize adenomas, especially if they are ectopic, it is helpful to combine planar imaging with cross-sectional (-hybrid) imaging using SPECT or SPECT/CT. With this approach, in combination with ultrasound the sensitivity for adenomas is known to be over 80 % up to 100 %. For multiglandular involvement or hyperplasia, a significantly lower detection rate is known, which, however, can be improved by a combination of planar and tomografic imaging. To what extend medication can influence the results of MIBI imaging is not well known. Glucocorticoids and calcium channel antagonist might have a negative influence on the uptake of MIBI. Another potential influencing factor could be the presence of P-glykoprotein in some adenomas, leading to a faster efflux of MIBI out of the adenoma cells and consecutively a lower detection rate.
Reference44 articles.
1. Pathologie der Nebenschilddrüse;S-Y Sheu-Grabellus;Pathologe,2015
2. Strategy of operative treatment of hyperparathyroidism using US scan and (99m)Tc-MIBI SPECT/CT;S Noda;Endocr J,2014
3. Primärer Hyperparathyreoidismus - Teil 1: Epidemiologie, Anatomie und Symptomatik;K Schlosser;Allg Viszeralchir Up2date,2013
4. Clinical value of Tc99m-MIBI SPECT/CT versus 4D-CT or US in management of patients with hyperparathyroidism;S Kedarisetty;Ear Nose Throat J,2019
5. Parathyroid pathology;J Guilmette;Surg Pathol Clin,2019